Document is current

Any future updates will be listed below

2414 Efficacy of ocrelizumab in people with multiple sclerosis is maintained despite high incidence of B-cell repopulation during treatment

Crossref DOI link: https://doi.org/10.1136/bmjno-2022-ANZAN.30

Published Online: 2024-02-01

Published Print: 2022-08

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark